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RESEARCH ARTICLE
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Abstract
Alzheimer disease (AD), Frontotemporal lobar degeneration (FTD), Amyotrophic lateral
sclerosis (ALS) and Parkinson disease (PD) have a certain degree of clinical, pathological
and molecular overlap. Previous studies indicate that causative mutations in AD and FTD/
ALS genes can be found in clinical familial AD. We examined the presence of causative and
low frequency coding variants in the AD, FTD, ALS and PD Mendelian genes, in over 450
families with clinical history of AD and over 11,710 sporadic cases and cognitive normal par-
ticipants from North America. Known pathogenic mutations were found in 1.05% of the spo-
radic cases, in 0.69% of the cognitively normal participants and in 4.22% of the families. A
trend towards enrichment, albeit non-significant, was observed for most AD, FTD and PD
genes. Only PSEN1 and PINK1 showed consistent association with AD cases when we
used ExAC as the control population. These results suggest that current study designs may
contain heterogeneity and contamination of the control population, and that current statisti-
cal methods for the discovery of novel genes with real pathogenic variants in complex late
onset diseases may be inadequate or underpowered to identify genes carrying pathogenic
mutations.
Author summary
In this study we provide further genetic evidence of the clinical, pathological and molecu-
lar overlap between neurodegenerative diseases. We screened the known Mendelian
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genes in Alzheimer disease (AD), Frontotemporal Dementia (FTD), Parkinson disease
(PD) and Amyotrophic Lateral Sclerosis (ALS) disease in over 13,292 individuals. We
report the presence of known pathogenic mutations in AD, FTD and PD genes in both
sporadic and familial late onset AD cases and even cognitively normal individuals, point-
ing to contamination of control cohorts with asymptomatic cases. We also observed an
enrichment, although not statistically significant, in most of AD, FTD and PD genes, rein-
forcing the idea of pathologic crossover among these diseases. However, the fact that
genes carrying known pathogenic mutation do not show significant association calls for a
reevaluation of current statistical methods.
Introduction
Neurodegenerative diseases like Alzheimer Disease (AD), Frontotemporal dementia (FTD),
Parkinson disease (PD) and Amyotrophic Lateral Sclerosis (ALS) share clinical and pathologic
features. Dementia is characteristic of AD and FTD, but may also present in PD and ALS [1].
In all these diseases we can observe two types of manifestations, either a rare and following
Mendelian inheritance, or a more common seemingly non-familial representation [2]. All
these diseases share the pathologic hallmark of presenting protein aggregates in different areas
of the central nervous system. The rare familial forms have been key to our understanding of
each disease’s pathology; these are well characterized by a dominant pathologic protein aggre-
gate in a specific location within the nervous system caused by the impairment of a specific set
of genes [2]. However, a clinical, and pathological crossover has been observed in the idio-
pathic forms [3] allowing for the assumption that different types of dementia may have over-
lapping genetic causes.
AD is the most common neurodegenerative disease affecting over 5.5 million Americans
[4]. AD’s main pathologic hallmark is the extracellular deposit of β-amyloid plaques, followed
by the presence of intracellular aggregates of neurofibrillary tangles of phosphorylated tau pro-
tein (MAPT). Pathogenic variants in APP, PSEN1 and PSEN2were thought to exclusively
cause early onset familial AD (EOFAD) [5], but the screening of some late onset families and
even sporadic cases, revealed that the contribution of familial genetic variants in APP, PSEN1
and PSEN2 in idiopathic cases cannot be neglected [6–8].
Intracellular aggregates of hyperphosphorylated tau (encoded by MAPT) is the second
neuropathological hallmark of AD. Tau aggregates also characterize a subgroup of FTD cases
(FTD-Tau) in which genetic linkage to MAPT was found [9]. The discovery of the gene
involved in tau deposits stimulated a series of studies seeking association between polymor-
phisms within MAPT and AD. Preliminary studies investigating the genetic relationship
between MAPT and AD produced contradictory results [10,11] although the latest reports
provide more compelling evidence that common variants in the MAPT region confer risk for
AD, particularly in cases who are non-carriers of the APOE ε4 allele [11–15]. Other familial
FTD cases that are negative for tau protein aggregates present ubiquitin inmunoreactivity
(FTD-U), which was initially associated with genetic variants in GRN [16]. Together with
MAPT,GRN genetic variants cause up to 50% of familial FTD cases, but GRN genetic variants
have also been regarded as risk factors for AD [17–20]. Other familial genes later associated
with FTD-U subtypes are C9ORF72, TARDBP, VCP, CHMP2B,UBQLN2 and FUS [21]. A
hexanucelotide repeat expansion in C9ORF72was identified as major risk factor for FTD
[22,23] although its pathogenicity towards ubiquitin reactive deposits is not well understood.
C9ORF72 is also the most common risk factor for familial ALS [24,25] and multiple studies
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have reported clinical AD cases with the full C9ORF72 expansion [26–29], extending the possi-
ble genetic continuum from AD to FTD and ALS. Shared genetic variants between FTD and
ALS have been found in TARDBP, VCP, UBQLN2 and FUS [30–35] but their association with
AD has not yet been reported. Other than the shared variants with FTD, the majority of famil-
ial ALS is caused by mutations in SOD1 [36,37]. Recently, mutations in OPTN, and PFN1 have
been reported in ALS kindreds [37]. No associations have yet been reported between ALS
genes and AD pathology, despite some attempts to demonstrate an association between com-
mon SOD1 variants and AD under the paradigm of a common oxidative stress pathway [38].
Finally, although AD is primarily characterized by cognitive deficits and PD by motor
impairment, a clinical and pathological cross-over has been identified in several instances by
the presence of dementia in PD patients [39] and motor symptoms in AD patients [40]. Patho-
logically, tau aggregates can be present to different degrees in sporadic PD [41] and more than
50% of people with AD show α-synuclein aggregates [41]. Lewy bodies, composed of α-synu-
clein aggregates, the pathological hallmark of PD, are attributed to pathogenic variants in the
SNCA gene; although genetic variants in LRRK2, PARK2, PARK7 and PINK1 have also been
linked to familial PD [42]. Combined meta-analysis of AD and PD GWAS revealed the lack of
variants that increase the risk of developing both diseases [43]; although later on, a genetic
overlap between AD and PD at the MAPT locus was detected [44] and recent studies have
detected pathogenic PARK2 mutations in sporadic early onset AD cases [15].
A genetic overlap among all these neurodegenerative diseases cannot be ignored, and may
certainly be underestimated since most of the previous studies performed either two by two
gene/disease analysis, which does not cover the full spectrum of genes, or GWAS, which does
not cover genetic variants across the frequency spectrum.
In a previous work we reported an enrichment of known pathogenic and novel rare variants
in APP, PSEN1, PSEN2,GRN and MAPT in LOAD families [45]. In this work, we expanded
our analysis to a thorough examination of all genes known to cause Mendelian forms of AD,
FTD, ALS, and PD. We evaluate the presence of rare and nonsynonymous genetic variants in
these 30 genes not only in a large independent familial dataset (467 families), but also in two
large sporadic cohorts, 851 in-house sporadic AD cases and controls and in the sporadic
ADSP (Alzheimer Disease Sequencing Project) dataset (https://www.niagads.org/adsp/
content/home, accessed August 2016).
Results
We identified 36 reported pathogenic Mendelian variants in 11 genes (APP, PSEN1, PSEN2,
GRN, MAPT, TARDBP, VCP, C9ORF72, LRRK2, PARK2, and PINK1) across the three datasets
examined (Table 1). Fifteen variants were found in 41 subjects (2.6%) from 19 different fami-
lies; 9 variants across 17 individuals (2.59% of cases and 1.59% of controls) from the Knight-
ADRC-NIA-LOAD (KANL) sporadic dataset; and 25 variants across 85 individuals (0.94% of
cases and 0.63% of controls) from the ADSP sporadic dataset (Table 1). The prevalence of
genetic variants between the sporadic and familial datasets tends to be higher in cases with
strong family history compared to the sporadic. In the AD genes 1.56% of the families, 0.94%
of the KANL sporadic cases, 0.27% of the KANL sporadic controls, 0.30% of the ADSP spo-
radic cases and 0.13% of the ADSP sporadic controls carried a previously reported pathogenic
variant. It was similar for FTD genes in which 0.88% families, 0.24% of the KANL sporadic
cases, 0.24% of the KANL sporadic controls, 0.24% of the ADSP sporadic cases and 0.02% of
the ADSP sporadic controls carried a pathogenic variant. The C9ORF72mutation is an intro-
nic hexanucleotide repeat that cannot be called by WES or WGS; therefore, we could not use
the sequence data to call this variant. We genotyped this variant by repeat-primed PCR in a
Mendelian genes in clinically diagnosed AD
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subset of unrelated 819 AD cases and 502 controls from the Knight-ADRC and in 872 unre-
lated familial AD cases from the NIA-LOAD dataset. We found the repeat expansion in 0.85%
of the unrelated cases and 0.57% of the families (10 individuals in total) carry the C9ORF72
repeat expansion. Interestingly, reported pathogenic mutations in PD genes were found as
much or even more frequent than AD mutations, especially within the ADSP dataset. These
mutations were found in eight families (1.77%), seven (0.87%) sporadic KANL, and up to 46
(0.42%) individuals from the sporadic ADSP.
In order to evaluate whether there was a differential finding of pathogenic variants between
cohorts, KANL and ADSP, we performed Chi-Squared and Fisher statistics. We used the unre-
lated KANL dataset and the sporadic ADSP to run association and Fisher analysis for the vari-
ants in Table 1 using Plink1.9. None of the examined variants showed differential frequency
between datasets except for PARK2 p.(Glu34fs), which was nominally more frequent in the
unrelated dataset (S2 Table). Using the familial dataset, we could evaluate the segregation pat-
tern and penetrance of these variants (Table 2).
Known AD pathogenic variants
Mutations in Mendelian AD genes are known to be autosomal dominant with complete pene-
trance; but we found that the variants identified in this study did not always present complete
penetrance or segregate perfectly with disease status (Table 2). First, the pathogenic variant
PSEN1 p.(Ala79Val) [46] was detected in a 67 yrs control from a large family with several
affected members and an average AAO around the seventies (Fam #1). Genotyping of the
mutation in up to 19 members of the family indicated incomplete penetrance (Fig 1A), given
the presence of phenocopies and some non-affected carriers, possible presymptomatic cases.
In addition, this variant was found in seven cases from the ADSP dataset with an average AAO
of 68 yrs. The pathogenic variant PSEN1 p.(Leu85Pro) [47] was detected in a family of four
affected and two non-demented individuals (Fam #2), but only one of the affected individuals
was a carrier of the genetic variant. The pathogenic variant PSEN1 p.(Gly206Ala) [48] was
found in one case of an AAO 55 yrs, self-reported Caribbean origin (Fam #3). This variant was
originally reported in 194 families of Caribbean Hispanic origin [48,49]. We also detected this
variant in four cases from the sporadic ADSP dataset, one of European American origin
(AAO = 63) and three with Hispanic ethnicity (mean AAO = 70). Variant PSEN2 p.(Asn141Ile),
also pathogenic [51], was detected in one family (Fam #5) and in one sporadic case (AAO = 53)
of the KANL cohort. However, after further examination of the clinical history of this partici-
pant we detected a reported family history of dementia (Supplementary results). Variant PSEN2
p.(Met174Val) [52] was detected in two families: Fam #6 was composed of six affected individu-
als and one diagnosed as non-demented. Only one affected and the cognitively-normal family
members were carriers of the variant (Fig 1B). Similarly, Fam #7 has five affected members and
three cognitively normal members, in which only one cognitively normal member (the marry-
in) was a carrier of the reported pathogenic variant. This variant was also observed in one con-
trol of the KANL sporadic dataset (ALA = 72) and in two cases (mean AAO = 82) and four cog-
nitively normal (64, 63, 84 and 85 yrs ALA) individuals from the sporadic ADSP dataset.
Together these results suggest that previously reported pathogenic variants in Mendelian
AD genes may present imperfect segregation, given the existence of phenocopies (Fam #1,
Fam #6); and/or incomplete penetrance due to the presence of older cognitive normal carriers
that may carry additional modifying factors. Also, their finding within the sporadic cohorts
calls for a reexamination of the non-affected carriers as possible presymptomatic individuals.
Known pathogenic variants in these genes were also observed exclusively within the “spo-
radic” datasets. Two affected individuals of the sporadic KANL cohort with age at onset
Mendelian genes in clinically diagnosed AD
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(AAO) in their 50s were carriers of a known pathogenic APP variant, p.(Ile716Val) [53]; and
variant APP p.(Val717Phe) [54] was found in one affected individual (AAO = 70) of the ADSP
Table 1. List of reported* pathogenic variants in genes for Alzheimer disease (AD), Frontotemporal dementia (FTD) and Parkinson disease (PD)
detected in the familial cohort, the sporadic KANL cohort and the ADSP sporadic cohort. We provide the number and percentage of families (NF),
cases (CA) and controls (CO) that were carriers of each variant.
Familial KANL & ADSP
(450 fams, 1090 CA, 441 CO)
sporadic KANL
(424 CA, 377 CO)
sporadic ADSP
(5844 CA, 4767 CO)
Disease GENE p.CHANGE NF (%) CA N (%) CO N (%) CA N (%) CO N (%) CA N (%) CO N (%)
AD APP p.(Ile716Val) - - - 2 (0.47) - - -
p.(Val717Phe) - - - - - 1 (0.02) -
PSEN1 p.(Ala79Val) 1 (0.22) 4 (0.37) 2 (0.45) - - 7 (0.07) -
p.(Leu85Pro) 1 (0.22) 1 (0.09) - - - - -
p.(Gly206Ala) 1 (0.22) 1 (0.09) - - - 4 (0.04) -
p.(His214Tyr) - - - - - 1 (0.02) -
p.(Leu226Arg) - - - 1 (0.24) - - -
p.(Arg269Gly) 1 (0.22) 1 (0.09) - - - - -
p.(Ala409Thr) - - - - - - 1 (0.02)
p.(Val412Ile) - - - - - 1 (0.02) -
PSEN2 p.(Ala85Val) - - - - - - 1 (0.02)
p.(Asn141Ile) 1 (0.22) 1 (0.09) - 1 (0.24) - - -
p.(Met174Val) 2 (0.44) 2 (0.18) 1 (0.06) 1 (0.27) 2 (0.03) 4 (0.08)
p.(Leu238Pro) - - - - 2 (0.03) -
TOTAL AD 7 (1.56) 10 (0.92) 3 (0.68) 4 (0.94) 1 (0.27) 18 (0.30) 6 (0.13)
FTD GRN p.(Arg110*) 1 (0.22) 4 (0.37) - - - 1 (0.02) -
p.(Thr382fs) 1 (0.22) 3 (0.28) 1 (0.23) - - - -
p.(Arg493*) - - - - - 4 (0.04) -
p.(Cys521Tyr) - - - - - 2 (0.03) -
MAPT p.(Gly289Arg) - - - - - - 1 (0.02)
p.(Arg406Trp) - - - 1 (0.24) 1 (0.27) 4 (0.07) -
p.(Gln424Lys) 1 (0.22) 3 (0.28) - - - - -
TARDBP p.(Asn267Ser) - - - - - 2 (0.03) -
p.(Asn390Ser) - - - - - 1 (0.02) -
VCP p.(Arg155His) 1 (0.22) 1 (0.09) - - - - -
TOTAL FTD 4 (0.88) 11 (1.01) 1 (0.23) 1 (0.24) 1 (0.27) 14 (0.24) 1 (0.02)
PD LRRK2 p.(Gly2019Ser) 1 (0.22) 3 (0.28) 1 (0.23) - - - -
PARK2 p.(Gln34fs) 1 (0.22) 1 (0.09) - 2 (0.47) - 3 (0.05) 3 (0.06)
p.(Pro113fs) 3 (0.67) 4 (0.37) - - - 2 (0.03) 2 (0.04)
p.(Met192Leu) 2 (0.44) 4 (0.37) 1 (0.23) 1 (0.24) 1 (0.27) 13 (0.22) 11 (0.23)
p.(Thr240Met) - - - 1 (0.24) 1 (0.27) 3 (0.05) 2 (0.04)
p.(Leu283Pro) - - - - - - 1 (0.02)
p.(Arg366Trp) - - - - 2 (0.53) - -
p.(Gly430Asp) - - - - - - 1 (0.02)
PINK1 p.(Arg464His) - - - - - 1 (0.02) -
p.(Arg492*) 1 (0.22) 1 (0.09) 1 (0.23) - - 1 (0.02) 3 (0.06)
TOTAL PD 8 (1.77) 13 (1.19) 3 (0.68) 4 (0.94) 4 (1.06) 23 (0.39) 23 (0.48)
TOTAL_ADFTDPD 19 (4.22) 34 (3.12) 7 (1.59) 11 (2.59) 6 (1.59) 55 (0.94) 30 (0.63)
* Reported pathogenic variants in http://www.molgen.ua.ac.be/ADMutations/ and http://www.molgen.vib-ua.be/PDMutDB/
** Genomic and positions correspond to GRCh37 genomic reference build.
https://doi.org/10.1371/journal.pgen.1007045.t001
Mendelian genes in clinically diagnosed AD
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cohort. The PSEN1 variant p.(Leu226Arg) [55] was detected in one affected participant
(AAO = 51) of the KANL cohort; variants PSEN1 p.(His214Tyr) [56] and p.(Val412Ile) [57]
were found in two cases (85 yrs and 84 yrs AAO) and variant p.(Ala409Thr) [58] was found in
one cognitively normal participant (ALA = 89) of the ADSP cohort. PSEN2 variant p.(Ala85-
Val) [59] was detected in one cognitively normal participant (ALA = 89) and variant p.
(Leu238Pro) [60] was found in two cases (80 and 63 yrs AAO) of the ADSP cohort.
Known FTD pathogenic variants
Mutations in FTD genes are also known to segregate in a dominant pattern. Among the seven
FTD genes examined, we observed four pathogenic variants in GRN, three pathogenic variants in
MAPT, two variants in TARDBP and one pathogenic variant in VCP. We also found the repeat
expansion C9ORF72 in several unrelated cases (0.85%) and in 10 individuals with family history.
The GRN variant p.(Arg110) [61] was present in three siblings and one cousin of a family
with a history of reported AD (Fam #8, Fig 1C), but only three of the affected members were
carriers of the genetic variant. This variant was also detected in one affected participant
(AAO = 74) of the ADSP cohort. The GRN variant p.(Thr382fs) [62] was detected in a female
AAO 60 yr with an AD diagnosis from the sporadic dataset. After examination of her clinical
history it was discovered that she had two siblings and one cousin diagnosed with dementia
(Fam #9). Genotyping of this variant in six family members revealed that the genetic variant
Table 2. Segregation pattern of reported pathogenic mutations detected in the familial cohort (452 families). The number of carriers and non-carriers
in both affected and cognitively normal family members is displayed, along with the average AAO for cases and average ALA for controls. The first reference
for each variant is also provided.
N cases (AAO) N controls (ALA)
Disease Gene Protein change Ref Family # Carriers Non-carriers Carriers Non-carriers
AD PSEN1 p.(Ala79Val) [46] 1 4 (70.75) 4 (73.5) 2 (67.5) 9 (80.7)
AD PSEN1 p.(Leu85Pro) [47] 2 1 (75) 3 (81 ± 3) 0 2 (78 ± 0)
AD PSEN1 p.(Gly206Ala) [48] 3 1 (55) 0 0 0
AD PSEN1 p.(Arg269Gly) [50] 4 1 (40) 0 0 0
AD PSEN2 p.(Asn141Ile) [51] 5 1 (45) 0 0 0
AD PSEN2 p.(Met174Val) [52] 6 1 (60) 5 (66 ± 8) 1 (79) 0
7 0 5 (68 ± 9) 1 (76) 3 (78 ± 2)
FTD GRN p.(Arg110*) [61] 8 4 (69 ± 3) 1 (67) 0 0
FTD GRN p.(Thr382fs) [62] 9 3 (64± 4) 1 (73) 0 2 (72 ± 4)
FTD MAPT p.(Gln424Lys) PC* 10 3 (70 ± 3) 2 (67+4) 0 1 (83)
FTD VCP p.(Arg155His) [69] 11 1 (56) 0 0 0
PD LRRK2 p.(Gly2019Ser) [71] 12 2 (61 ± 0) 2 (68 ± 5) 1 (92) 0
13 1 (65) 1 (69) 0 2 (86 ± 5)
PD PARK2 p.(Gln34fs) [73] 14 1 (79) 1 (82) 0 1 (84)
PD PARK2 p.(Pro113fs) [75] 15 2 (80 ± 4) 2 (74 ± 4) 0 1 (81)
16 1 (86) 2 (65 ± 5) 0 1 (81)
17 1 (78) 2 (80 ± 3) 0 0
PD PARK2 p.(Met192Leu) [76] 18 3 (79 ± 5) 0 1 (80) 0
19 1 (55) 0 0 0
PD PINK1 p.(Arg492*) [80] 20 1 (68) 2 (59 ± 1) 1 (73) 1 (76)
Reported pathogenic variants in http://www.molgen.ua.ac.be/ADMutations/ and http://www.molgen.vib-ua.be/PDMutDB/
Genomic and positions correspond to GRCh37 genomic reference build.
*PC: personal communication in 2005 by Brice to AD&FTDMDB Curator.
https://doi.org/10.1371/journal.pgen.1007045.t002
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was present in all members affected by dementia, and one young cognitively normal partici-
pant (ALA = 65). Pathology reports available indicated that the index individual had AD
pathology and Pick bodies with a frontotemporal lobar atrophy pattern consistent with Pick’s
disease; and the two siblings were later pathologically diagnosed as FTD and as non-AD
dementia. Two other variants in GRN p.(Arg493) [63] and p.(Cys521Tyr) [64] were detected
in the sporadic ADSP cohort: GRN p.(Arg43) was found in 4 affected participants (average
AAO = 73) and p.(Cys521Tyr) was found in 2 affected participants (average AAO = 82.5). The
incomplete penetrance observed for GRN within the families can be the result of phenocopies
(Fam #8) or presymptomatic cases (Fam #9).
The MAPT variant p.(Gly389Arg) [65] was found in one cognitively normal participant
(ALA = 91) from the ADSP cohort. MAPT variant p.(Arg406Trp) [66] was detected in two par-
ticipants of the sporadic dataset, both cognitively normal in their 60s with no symptoms of pre-
symptomatic AD (not by imaging or CSF Aβ levels). MAPT variant p.(Gln424Lys) (personal
communication in 2005 by Brice to AD&FTDMDB Curator) was detected in one family (Fam
#10) in which three of the five affected members were carriers of the variant.
Variants in TARDBP were exclusively found in the ADSP cohort. Variant p.(Asn267Ser)
[67] was detected in two affected members (Average AAO = 77) and variant p.(Asn390Ser)
[68] was detected in one affected member with AAO 74 yrs.
The VCP variant p.(Arg155His) [69] was detected in Fam #11 but segregation could not be
performed since DNA was only available for one of the affected members.
Known PD pathogenic variants
Mutations in PD genes present different patterns of segregation; SNCA and LRKK2 are known
to cause dominantly inherited PD, whereas PARK2, PARK7 and PINK1 are known to cause
Fig 1. Pedigree structure of families’ carriers of genetic variants. (a) PSEN1 p.(Ala79Val), (b) PSEN2 p.
(Met174Val), (c) GRN p.(Arg110*). Age at onset (AAO), age at last assessement (ALA) and APOE status is
provided for each genotyped individual.
https://doi.org/10.1371/journal.pgen.1007045.g001
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early onset PD with a recessive inheritance mode [70]. We detected 10 different known patho-
genic PD variants in LRKK2, PARK2 and PINK1, in 70 different carriers, all of whom were het-
erozygous for the variant. One LRRK2 variant, p.(Gly2019Ser) [71], was only present in two
families (Fam #12, Fam #13). Fam #12 includes five members, four diagnosed with AD (two
carriers) and one cognitively normal (a carrier heterozygous for p.(Gly2019Ser)). Fam #13 is
composed of two affected individuals (one carrier) and two cognitively normal (no carriers).
Mutations in the LRRK2 gene are the most common genetic cause of PD; but this gene is also
known to have pleomorphic pathology [72] and the penetrance of the variant p.(Gly2019Ser)
is known to vary in different populations and ages [73], so, the incomplete penetrance
observed here is not surprising.
Seven variants were detected in PARK2: p.(Gln34fs) [74] was found in one case (AAO = 79)
from Fam #14 although the other case was a non-carrier, in two affected participants (AAO of
31 and 82 yrs) of the KANL sporadic dataset, and in three cases (average AAO = 83) and three
cognitive normal participants (average ALA = 86) from ADSP. PARK2 variant p.(Pro113fs)
[75] was present in four of 10 cases from three families (Fam #15, Fam #16, Fam #17) and in
two cases (AAO 73 and 83 yrs) and two cognitively normal (ALA 64 and 87) participants of
the ADSP cohort. In our study, variant PARK2 p.(Met192Leu) [76] was the most common of
the PD mutations. All four members from Fam #18 (three cases and one control) were carriers
of the genetic variant, as was the case from Fam #19 (AAO = 55). Within the KANL this vari-
ant was found in one affected (AAO = 64) and one cognitively normal (ALA = 68) member.
Up to 13 affected carriers (Average AAO = 88±7) and 11 cognitively normal carriers (average
ALA = 84±5) were detected in the ADSP cohort. Four other variants in PARK2 were exclu-
sively found in the sporadic cohorts. Variant p.(Thr240Met) [77] was detected in one affected
(AAO = 77) and one cognitively normal (ALA = 64) member of the KANL sporadic cohort,
and in three affected (average AAO = 82±10) and two cognitively normal (average ALA = 88)
members of the ADSP sporadic cohort. PARK2 variants p.(Leu238Pro) [78] and p.(Gly430Asp)
[76] were found in the same cognitively normal individual of the ADSP cohort (ALA = 68),
whereas PARK p.(Arg366Trp) [79] was found in two non-affected carriers (average ALA = 65)
from the KANL sporadic cohort.
Finally, two variants were detected in PINK1. Variant p.(Arg464His) was found in one
affected (AAO = 86) participant of the ADSP cohort. Variant p.(Arg492) [80] was present in
only one case (AAO = 68) and one cognitively normal (ALA = 73) member from Fam #20,
and in one affected (AAO = 65) and three non-affected (ALA 73,86,88) individuals from the
ADSP cohort.
Mutations in PARK2 and PINK1 are known to cause early onset PD (AAO range 12–58 yr)
with a recessive pattern of inheritance. Segregation could not be determined in our study due
to lack of familial stages. With the exception of the case in Fam #20 (AAO of 55), the individu-
als reported here all had an AAO > 60, suggesting that these PARK2 and PINK1 variants
would be modifiers rather than causative of AD. For a full description of all known pathogenic
variants detected, see Supplementary Results.
Gene based analysis
Once we confirmed that known pathogenic mutations in the AD, FTD and PD genes can be
found in sporadic as well as in late-onset familial samples, we wanted to determine if an overall
increase of low frequency non-synonymous coding variants can be found in these genes in AD
cases compared to cognitively normal participants. We performed this analysis in our unre-
lated dataset and in the sporadic ADSP dataset. The cases in the unrelated KANL dataset pres-
ent a larger enrichment of rare pathogenic variants compared to the cases of the sporadic
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ADSP dataset (Table 3). In both datasets, the enrichment increases when we focus on very rare
non-synonymous variants (Table 3). None of these enrichments was significant after multiple
test correction, but we observe some suggestive and nominally significant results.
Within the unrelated KANL cohort we found CHMP2B (OR = 2.24, P = 0.06) and VPS35
(OR = 6.77, P = 0.05) to have suggestive significance-values, and EIF4G1 (OR = 1.71, P = 0.01)
to be nominally significant for rare variants, those with minor allele frequency below 1% and a
predicted high or moderate effect on the final protein (MAF1% HM). Also, the global effect
of AD genes (APP, PSEN1 and PSEN2) was nominally significant (OR = 2.31, P = 0.028) if we
Table 3. Burden test for KANL and ADSP unrelated datasets. Collapsing and combine (CMC) test of rare variants by Fisher’s exact test for (i) variants
with a MAF1% and categorized to have a high or moderated effect (MAF1% HM) and (ii) singleton variants categorized to have a high or moderated effect
(AC1 HM), for the unrelated datasets analyzed in this study (unrelated KANL and Sporadic ADSP). Number of polymorphic variants (N), odds ratio (OR) and
two sided pvalue (P) are given. Enriched genes with nominally significant pvalues are bold highlighted.
MAF1% HM AC1 HM
Unrelated KANL (N = 1235) Sporadic ADSP (N = 10280) Unrelated KANL (N = 1235) Sporadic ADSP (N = 10280)
Disease Gene N OR P N OR P N OR P N OR P
AD APP 19 1.522 0.340 93 0.958 0.396 15 3.106 0.103 31 1.122 0.688
AD PSEN1 10 3.380 0.122 51 1.656 0.990 10 3.380 0.122 23 1.520 0.880
AD PSEN2 24 1.011 1.000 74 0.897 0.123 11 1.471 0.763 18 0.810 0.414
AD PRNP 3 1.259 0.762 28 1.001 0.534 2 0.838 1.000 8 5.677 0.991
FTD CHMP2B 7 2.238 0.059 25 0.878 0.243 4 NA 0.130 10 0.202 0.026
FTD FUS 12 0.552 0.159 61 0.976 0.463 9 0.416 0.315 18 0.648 0.246
FTD GRN 26 0.656 0.119 94 1.044 0.679 19 1.444 0.494 12 4.056 0.991
FTD MAPT 33 1.101 0.791 97 0.905 0.178 23 0.639 0.299 37 1.064 0.635
FTD TARDBP 4 1.118 1.000 19 0.867 0.197 2 NA 0.503 8 0.810 0.517
FTD TBK1 18 0.956 1.000 77 1.207 0.902 13 2.820 0.160 22 1.419 0.843
FTD VCP 15 0.727 0.459 41 1.071 0.701 12 0.595 0.398 9 6.489 0.995
PD LRRK2 54 1.142 0.591 267 0.994 0.488 38 0.705 0.318 43 1.461 0.910
PD PARK2 20 0.831 0.577 82 0.971 0.407 9 1.048 1.000 31 1.284 0.804
PD PARK7 8 1.471 0.763 30 0.916 0.389 6 1.680 0.694 18 1.274 0.768
PD PINK1 29 0.935 0.866 91 0.893 0.212 23 0.835 0.673 27 1.105 0.671
PD SNCA 3 1.399 0.734 11 0.866 0.283 2 NA 0.503 - - -
PD UCHL1 6 1.682 0.521 31 1.045 0.621 5 3.365 0.384 11 2.162 0.933
PD ATP13A2 51 0.750 0.149 195 0.837 0.006 32 1.018 1.000 79 0.897 0.357
PD GIGYF2 30 0.769 0.402 165 1.040 0.692 22 0.623 0.377 70 1.146 0.752
PD HTRA2 11 1.231 0.595 50 1.196 0.909 6 0.166 0.098 25 0.636 0.176
PD PLA2G6 40 0.976 1.000 136 0.999 0.510 26 0.977 1.000 17 0.911 0.518
PD FBXO7 20 1.452 0.322 71 1.030 0.611 17 1.200 0.809 42 1.035 0.603
PD VPS35 7 6.771 0.045 46 0.913 0.361 5 3.365 0.384 30 0.868 0.421
PD EIF4G1 40 1.713 0.010 204 1.016 0.606 26 1.146 0.843 100 0.954 0.447
PD DNAJC16 29 1.404 0.186 143 0.918 0.227 20 1.567 0.374 69 0.833 0.262
ALS SOD1 1 0.000 0.208 8 0.810 0.327 - - - 1 NA 1.000
ALS OPTN 14 0.835 0.684 68 1.092 0.750 12 0.836 0.779 30 1.060 0.631
ALS UBQLN2 5 1.688 0.346 - - - - - - - - -
ALS PFN1 1 0.000 0.456 18 1.128 0.716 1 0.000 0.456 3 1.621 0.831
ALS SQSTM1 30 0.758 0.271 99 0.945 0.295 22 0.694 0.399 24 0.957 0.537
TOTAL AD 56 1.174 0.439 246 0.988 0.443 38 2.315 0.028 80 1.283 0.885
TOTAL FTD 115 0.877 0.378 414 0.980 0.367 82 1.057 0.907 116 1.092 0.711
TOTAL PD 348 1.049 0.688 1522 0.976 0.276 237 0.897 0.492 562 1.013 0.573
TOTAL ALS 51 0.823 0.367 193 0.980 0.410 35 0.698 0.307 58 1.070 0.649
https://doi.org/10.1371/journal.pgen.1007045.t003
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considered only very rare variants, those with just one allele count in the population and a pre-
dicted high or moderate effect on the final protein (AC1 HM).
The enriched effect of CHMP2B remained significant when we considered only APOE ε4
carriers; some of the AD genes became nominally significant (e.g. APP and PSEN2) and the
global effect of AD genes resulted in nominal significance for rare variants and significant after
multiple test correction (Total AD, OR = 14.76, P = 1.83×10−4) when we considered very rare
variants (S3 Table). EIF4G1 remained nominally significant (OR = 2.01, P = 0.02) for the set of
APOE ε4 non-carriers; FBXO7 became nominally significant (OR = 3.09, P = 0.03) and VPS35
gained suggestive significance (OR = 7.05, P = 0.06) within the set of rare variants (MAF1%
HM). In addition, the global effect of very rare variants (AC1 HM) from FTD genes was also
nominally significantly associated (OR = 1.84, P = 0.04) with APOE ε4 non-carriers (S4
Table).
Within the sporadic ADSP cohort, none of the enriched genes presented significant p-val-
ues (Table 3). However, PSEN1 resulted in nominally significant association with the APOE ε4
non-carrier for both sets, rare (OR = 2.14, P = 0.05) and very rare variants (OR = 2.76,
P = 0.02) (S3 Table).
Because the lack of significant associations could be due to the sample size, we decided to
perform gene-based analyses comparing all the unrelated KANL cases (n = 672) or the spo-
radic ADSP cases (N = 5,679) with the non-Finnish European (NFE) ExAC population as a
cognitive normal dataset (n = 33,000). The coverage of the tested genes in ExAC and in our
population is comparable. PSEN1 appeared as nominally significantly enriched in these two
cohort cases for the set of rare variants (MAF1% HM); and it was statistically significant for
sporadic ADSP cases within the very rare set of variants (OR = 3.134, P = 3.34×10-5). Interest-
ingly, PINK1 appeared as significantly associated with the unrelated cases examined regardless
of the set of variants tested. EIF4G1 also remained significantly associated with unrelated
KANL cases within the rare variants subset (OR = 1.69, P = 8.96×10−4) and for sporadic ADSP
cases within the very rare set of variants (S5 Table). No statistical association was found for the
overall AD, FTD and PD genes in either the KALN or ADSP dataset (S5 Table).
Discussion
Recent reports indicate that rare variants in AD Mendelian genes, APP, PSEN1 and PSEN2,
cause, contribute and modify risk for AD [12,45]. Given the clinical and pathologic overlap
between AD and other common neurodegenerative diseases, a genetic contribution toward
AD risk by genes involved in other diseases has been sought for some time now. However,
because of their rarity, contributions towards disease at a genome-wide level of significance
are difficult to achieve without large cohorts and well characterized populations. This is the
first study that thoroughly screens for pathogenic mutations in known neurodegenerative
genes and evaluates the contribution of low frequency variants in these genes towards AD in a
large cohort of sporadic and densely affected LOAD families.
In previous studies, we sequenced APP, PSEN1, PSEN2,GRN, MAPT and C9ORF72 in late-
onset families and detected known pathogenic mutations in 2.9% of the families [45,81]. In
this study, we detected 10 families (2.2%) with carriers of a known pathogenic mutation in
APP, PSEN1, PSEN2,GRN or MAPT, and an additional 0.57% of the families with the
C9ORF72 repeat. Overall, 0.82% fLOAD participants carried a mutation in AD genes, and
0.63% of them carried a mutation in FTD genes.
This study extends previous findings to sporadic cases, from two different cohorts: sporadic
cases from the Knight-ADRC (KANL) and late-onset cases and cognitively normal participants
from the ADSP. We found that 0.87% of the KANL participants carry a known pathogenic
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mutation in AD (0.94% of cases and 0.27% of controls) and FTD (0.24% of cases and 0.27% of
controls) genes, and 0.36% of the ADSP participants carry a known pathogenic mutation in AD
(0.30% of cases and 0.13% of controls) and FTD (0.24% of cases and 0.02% of controls%) genes.
This suggests that it is possible to find known pathogenic mutations of AD and FTD genes in
familial LOAD as well as sporadic AD with the same probability. Another important finding is
that we found a similar portion of cases and families with a mutation in the AD genes vs the FTD
genes. Mutations in AD genes were found in 0.82% of fLOAD participants and FTD genes in
0.63% of that population. It is important to note that we found that 0.85% of the sporadic KANL
cases had the C9ORF72 expansion repeat that had to be genotyped independently, because current
sequencing methods are not able to capture this variant. Nonetheless, the proportion of individu-
als with FTD genes in the ADSP dataset is underestimated because we could not screen for the
C9ORF72 repeat. It is also important to note that known pathogenic mutations were found in the
cognitive normal participants. For this analysis, we only focused on known and well characterized
pathogenic mutations. Those variants were classified as pathogenic because they were initially
found in early-onset cases, segregated with disease status, were not present in the general popula-
tion and/or functional analyses confirmed that those variants are pathogenic.
The clinical complexity of dementias has raised speculation that many other neurological
diseases are misdiagnosed as AD [82]. In several previous studies there has been the suspicion
for FTD to masquerade clinically as AD [57,83]; therefore it could be argued that the detection
of known FTD pathogenic variants (GRN—p.(Arg110) and GRN- p.(Thr382fs)), or C9ORF72
in the KANL cohort is due to the presence of misclassified FTD cases. Autopsy reports from
some members of these families describe pathological variability among the affected carriers,
with some members presenting with AD and Pick body pathology, and others presenting with
“frontotemporal nonspecific neuropathology”. Hence, instead of misclassified cases, we may
be facing a pleomorphic pathology of these GRN variants, an issue observed previously, specifi-
cally in familial FTD [84]. This pleomorphism is expanded by the recent association of GRN
rare variants in autopsy confirmed cases with Lewy Body dementia (LBD) [85].
Pleomorphic pathology has also been described in several instances for LRKK2 genetic vari-
ants [42,71] which, other than being the most common cause for autosomal late onset PD, has
also been associated with tau pathology and AD [86,87]. The finding here of a LRRK2 genetic
variant p.(Gly2019Ser) (Fam #13) in a clinically diagnosed AD case would amplify the pleo-
morphic range of LRRK2 variants. Alternatively, it could be that the pathogenic PD variants
observed in LRRK2, PARK2 and PINK1 could be misdiagnosed cases of LBD. LBD may ini-
tially present with cognitive impairment and be misdiagnosed as AD, or as PD if it starts with
parkinsonism. In addition, Lewy bodies, sometimes present in AD, are hallmarks of DLB and
PD, and Aβ plaques and Tau tangles often coexist in LBD and PD, for which a synergy and a
genetic correlation among these three conditions has been suggested [88–90].
We have observed that variants usually regarded as causing pure early onset forms of AD,
FTD, PD or ALS can be associated with a wide pathological spectrum. They may also present
to different extent in families with a late onset. Both highly penetrant variants (GRN—p.
(Arg110)), and others with mild penetrance (PSEN2 –p.(Met174Val)) have been observed.
Incomplete penetrance can be (in some instances) explained by the presence of pre-symptom-
atic cases; but the presence of phenocopies also suggests that the penetrance may not be as
high as previously thought. (Fig 1B, Fam #6). There are reported cases in which autosomal
dominant AD variants present with a later AAO and clinically mimic LOAD [91]. The
observed genetic overlap of AD with other neurodegenerative diseases suggests that future
studies focused on gene discovery for AD using late onset families should not rely solely on
segregation patterns; additional methods that take into account endophenotypes, gene-net-
works and pathway analysis need to be developed and implemented in routine analysis.
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The confirmation that pathogenic variants in causal Mendelian genes are found in late
onset individuals, with or without family history, serves to model the system and alert us as to
what we might expect of other genes that potentially carry pathogenic mutations. We observed
an enrichment, although not statistically significant, in most of AD, FTD and PD genes in
both KANL and ADSP cohorts. The pathological cross-over with ALS genes would not be so
obvious despite the significant association reported between ADSP cases when compared to
ExAC population. Nevertheless, from the results of this study we can observe that there are
certainly molecular crossovers between AD, FTD, PD and ALS that point towards common
etiologic pathways. These gene-based analyses performed suggest an enrichment of non-syn-
onymous rare variants in these Mendelian genes in the cases of both cohorts, KANL and
ADSP; this enrichment is stronger when we only consider very rare variants (AC1 HM),
although none of the analysis was statistically significant. Only PSEN1 and PINK1 showed a
consistent and steady association pattern when we compared the cases from KANL or ADSP
against ExAC as cognitive normals. Therefore, the lack of genome-wide significant p-value
could be due to power, but other alternative explanations exist. One possibility is that given the
late onset appearance of the disease we may be including many potential asymptomatic cases
among the cognitively normal cohorts, as we see in some of the families evaluated (Fam #1)
and by the identification of sporadic cognitive normals below 70 yrs who are carriers of patho-
genic mutations (e.g. APP variants p.(Ile716Val) and p.(Val717Phe)). This leads to a reevalua-
tion of current study designs; first, more pathologically confirmed elderly cognitive normals
should be incorporated and prioritized. Second, more extensive preliminary screenings should
be in place for proper genetic counselling and screening of families before incorporating indi-
viduals into studies looking for novel genetic causes. Another possibility is that current analyti-
cal and statistical methods are inadequate to detect real causal genes involved in the disease. In
this study, we have shown that despite having in our cohort individuals carrying known and
causal pathogenic variants, current gene-based analysis would have not detected these genes as
implicated in the disease. On the other hand current gene-based methods have been able to
find genome-wide p-values for genes enriched for risk, but not pathogenic variants such as
APOE, TREM2, PLD3, ABCA7 and SORL1 [92–95].
Study limitations
We would like to conclude by reinforcing that despite the limitations of this study the results
obtained are sound and in the expected direction. First, this research is based on clinical AD
participants and cognitive normals, so we cannot rule out the presence of presymptomatic
cases, comorbidities, phenotypic changes with disease evolution, or even misdiagnoses, as we
have already stated. This limits the power of this study to establish causality of the detected
pathogenic variants and it could as well be limiting our statistical power and enrichment. Sec-
ond, sporadic and familial AD are categorically different entities, despite the fact that we
believe the genetic architecture and molecular load are largely similar [91]. However, the com-
plex and heterogeneous presentation of AD makes it difficult to recruit large cohorts with
good phenotypic characterization. Therefore, despite our effort to increase our sample size by
creating an unrelated cohort, we are still underpowered to detect significant association for
genes that we know are directly involved in the pathogenicity of the disease. Nonetheless, these
findings highlight the need to join efforts to gather large sample sizes. Finally, we are also
aware that the comparison against ExAC data has some methodological flaws. We even
acknowledge the possible presence of pre-symptomatic cases within the Exac database. That is
why we only consider those results as illustrative of what could be the genetic load when a
larger dataset of cognitive normal participants is available.
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Material and methods
Washington University cohort
Samples from the Washington University School of Medicine (WUSM) site included in this
study were recruited by either the Charles F. and Joanne Knight Alzheimer’s Disease Research
Center (Knight-ADRC) at the Washington University School of Medicine in Saint Louis or
the National Institute on Aging Genetics Initiative for Late-Onset Alzheimer’s Disease (NIA--
LOAD). From this point onwards, we will refer to these samples as KANL (Knight-ADRC--
NIA-LOAD). This study was approved by each recruiting center’s Institutional Review Board.
Research was carried out in accordance with the approved protocol. Written informed consent
was obtained from participants and their family members by the Clinical and Genetics Core of
the Knight ADRC. The approval number for the Knight ADRC Genetics Core family studies is
201104178.
All the cases received a diagnosis of dementia of the Alzheimer’s type (DAT), using criteria
equivalent to the National Institute of Neurological and Communication Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Association for probable AD [96,97]. Cog-
nitively normal participants received the same assessment as the cases, and were deemed non-
demented. Written consent was obtained from all participants.
Sporadic cohort. The Knight Alzheimer’s Disease Research Center (Knight ADRC) at
the WUSM recruits volunteer participants for longitudinal studies of aging and dementia [98].
We selected 424 cases clinically diagnosed with possible or probable AD [96] and 377 cogni-
tively normal participants with a Clinical Dementia Rating (CDR) of 0 (no dementia) at last
assessment.
Familial cohort. The NIA-LOAD Family Study has recruited multiplex families with two
or more siblings affected with LOAD across the United States. A description of these samples
has been reported previously [99]. We selected individuals for sequencing from families
(described previously [45]) in which APOEε4 did not segregate with disease status, and in
which the proband of the family did not carry any known mutation in APP, PSEN1, PSEN2,
MAPT,GRN or C9ORF72. The final cohort consisted in 1,402 samples from 430 families, of
which 997 were clinically diagnosed as AD, 418 were relatives with CDR = 0 at last assessment,
and 51 were cases initially diagnosed as AD but turned out to have another diagnosis (OT)
after pathological examination.
Unrelated cohort. To perform burden tests, we generated a cohort of unrelated European
American individuals by combining the sporadic cohort (CA and CO) with the youngest case
of each family and an unrelated CO (usually a marry-in). To ensure unrelatedness we calcu-
lated Identity by Descent (IBD) with PLINK1.9 and required that in addition to an IBD0.2,
all possible pairs had a Z00.75 and a Z10.25. To ensure all individuals were from European
American ethnicity we ran PCAs against the 1000G database. This resulted in an unrelated
case-control dataset of 1,235 individuals (672 cases and 563 controls) (Table 4).
ADSP cohort
The Alzheimer’s Disease Sequencing Project (ADSP) is a collaborative work of five indepen-
dent groups across the USA that aims to identify new genomic variants contributing to
increased risk for LOAD. (https://www.niagads.org/adsp/content/home). During the discov-
ery phase, they generated WGS data from members of multiplex AD families and whole
exome sequence WES data collected in a large case-control cohort. These data are available to
qualified researchers through the database of Genotypes and Phenotypes (https://www.ncbi.
nlm.nih.gov/gap Study Accession: phs000572.v7.p4).
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Sporadic cohort. The case-control cohort on ADSP consists of 10,909 individuals, 5,844
cases, 4,767 cognitive normal participants and 298 reported as OT, mostly of European-Ameri-
can ancestry (98%). We downloaded a plink file available for sequence data after joint calling
and QC analysis. We used the entire dataset to search for presence of pathogenic variants but
we later restricted our working dataset to 10,280 IDs (5,679 cases and 4,601 controls) of Euro-
pean-American ethnicity corroborated by PCAs.
Familial cohort. The familial cohort of the ADSP consists of 582 individuals from 111
multiplex AD families from European-American, Caribbean Hispanic, and Dutch ancestry
(Details about the samples are available at NIAGADS). We downloaded raw data (.sra format)
from dbGAP for 143 IDs (113 cases and 23 controls) from 37 multiplex families of European-
American ancestry that were incorporated with the KANL familial dataset.
Sequencing
Samples coming from the KANL site were sequenced using either whole-exome sequencing
(WES, 83.53%) or whole-genome sequencing (WGS, 16.46%). Exome libraries were prepared
using Agilent’s SureSelect Human All Exon kits V3 and V5 or Roche VCRome. Both, WES
and WGS samples were sequenced on a HiSeq2000 with paired ends reads, with a mean depth
of coverage of 50x to 150x for WES and 30x for WGS.
Bioinformatic analysis and QC
We performed joint analysis and quality control (QC) for all samples coming from the KANL
site as well as for the ADSP familial study-design downloaded from dbGAP. Whether we
started from BAM files or SRA files, all were converted to fastq files. Alignment was conducted
against GRCh37.p13 genome reference. Variant calling was performed separately for WES
and WGS following GATK’s 3.6 Best Practices (https://www.broadinstitute.org/gatk/) and
restricted to Agilent’s V5 kit plus a 100 bp of padding added to each capture target end. WGS
Table 4. Demographic data for the cohorts employed in this study and analysis plan.




Cases 1090 72.30±9.20 36–99 63% 72% Discovery
Controls 441 83.95±8.95 39–104 58% 52%




Cases 424 66.13±9.77 43–89 49% 60% Discovery




Cases 672 65.59±9.29 36–98 52% 70% GENE-based




Cases 5844 75.50±9.33 40–107 58% 42%
Controls 4767 86.78±5.47 42–107 59% 15%




Cases 5679 75.51 ± 8.83 40–107 58% 42%
Controls 4601 84.72 ± 4.72 49–107 52% 15%
* Age At Onset (AAO) for cases and Age at Last Assessment (ALA) for controls.
https://doi.org/10.1371/journal.pgen.1007045.t004
Mendelian genes in clinically diagnosed AD
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007045 November 1, 2017 14 / 22
data was filtered to remove low complexity regions, and regions with excessive depth. Only
those variants and indels that fell within the above 99.9% confidence threshold were consid-
ered for analysis; additional variant filters included allele-balance (AB = 0.3–0.7), quality depth
(QD5 for indels and QD2 for SNPs), and missingness (geno = 0.05). Variants out of
Hardy Weinberg equilibrium (P<1x10-6) or with differential missingness between cases and
controls, WES and WGS or different sequencing platforms were removed from analysis. In
addition, individuals with more than 10% of missing variants and whose genotype data indi-
cated a sex discordant from the clinical database were removed from dataset. Finally, individ-
ual and familial relatedness was confirmed using PLINK1.9 (https://www.cog-genomics.org/
plink2/ibd) and an existing GWAS dataset for these individuals. Functional impact and popu-
lation frequencies of variants were annotated with SnpEff [100]. At this point we separated
familial from sporadic KANL datasets and generated the unrelated dataset.
For the ADSP case-control dataset we downloaded plink file after alignment, variant calling
and QC had been performed to which we performed additional QC. Briefly, we checked for
allele-balance (AB = 0.3–0.7) and differential missingness between cases and controls. We used
the entire dataset for discovery of pathogenic variants but we later restricted our analysis to indi-
viduals with self-reported non-hispanic white ethnicity that we corroborated with PCAs.
C9ORF72 hexanucleotide repeat genotyping. The presence of the expanded hexanucleo-
tide repeat and the number repeats for the longest allele was determined by previously
reported methods for both a modified repeat-primed PCR and a fluorescence-based fragment
size analysis as previously reported [80,101,102]. Briefly, repeat-primed PCR was performed
containing 100 ng genomic DNA, 1x FastStart PCR Master Mix (Roche Applied Science, Indi-
anapolis, IN, USA), 3.5% DMSO, 1x Q solution (Quiagen, Valencia, CA) and 0.18 mM of dea-
zaGTP (NEB, Ipswich, MA). PCR products were run on a Genetic Analyzer 3500 (Applied
Biosystems) and analyzed using GeneMapper. A sample was considered positive for a repeat
expansion when assay replicates demonstrated >30 peaks and a decrementing saw-tooth pat-
tern with 6 bp periodicity.
Selection of candidate genes, variants and analysis
We focused our analysis on genes and variants reported as pathogenic and causing disease in a
Mendelian pattern in AD, FTD, PD or ALS. For AD and FTD we restricted our analysis to
those genes listed in the AD&FTD mutation database (http://www.molgen.vib-ua.be/
ADMutations/, accessed November, 2016); particularly, we focused on APP, PSEN1 and
PSEN2 for AD and CHMP2B, FUS,GRN, MAPT, TARDBP, TBK1 and VCP for FTD. For PD
we started off with those genes and variants listed in the PD mutation database (http://www.
molgen.vib-ua.be/PDMutDB/, accessed November, 2016), namely, LRRK2, PARK2, PARK7,
PINK1 and SNCA;we also included UCHL1,ATP13A2, GIGYF2, HTRA2,PLA2G6, FBXO7,
VPS35, EIF4G1 and DNAJC16 for being reported as causative of Mendelian PD in several occa-
sions [103,104]. To our knowledge, there is no ALS mutation database so we restricted our
analysis to those genes consistently reported in the literature as causative of familial ALS, i.e.
SOD1,OPTN,UBQLN2 and PFN1 [37]; other familial ALS genes like FUS,VCP, UBQLN2 and
SQSTM1 are included as FTD causing.
Single variant analysis: Known pathogenic variants. The AD & FTD and PD mutation
databases are continuously updated with information on genetic variants, reported in the liter-
ature, at scientific meetings or via direct submission (pathogenic or not) that occur in the cod-
ing region of genes related to AD, FTD, and PD. We screened our sporadic and familial
cohorts for presence of already reported pathogenic variants and evaluated their pattern of seg-
regation in the familial dataset.
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Gene-based analysis. We sought to estimate whether our cohort was enriched in low fre-
quency variants in the AD, FTD, PD, ALS genes. To estimate the effect size of low frequency vari-
ants in a gene-based context we performed exact CMC (Collapsing and combine rare variants)
burden test, as implemented in rvtest [105] for each gene and aggregated set of genes that confer
risk towards AD, FTD, PD and ALS. Burden analysis was performed within the cases of the
KANL unrelated cohort (671 cases, 563 controls) and within the cases of the ADSP dataset and the
ExAC non-Finish European cohort as controls. Only those variants predicted to have a high
(frameshift, splice acceptor/donor, stop gained/lost), or moderate (in-frame deletion/insertion,
missense variant) effect according to SnpEff [100] were included. We further applied two fre-
quency filters (i) a minor allele frequency below 1% (using ExAC non-Finnish European fre-
quency as cut-off) and considered having a high or moderate (HM) effect (MAF1% HM), (ii)
those variants with allele count equal to one (using the ExAC non-Finnish European counts as
cut-off) and considered to have a high or moderate (HM) effect. The second threshold AC1 is
based on the frequency of variant PSEN1 rs63749824, p.(Ala79Val) (a known AD pathogenic vari-
ant) in the ExAC non-Finnish European dataset. Any variant more frequent than this conservative
threshold would not be expected to be a highly penetrant pathogenic mutation. This methodology
has been previously used to reassess the effect of rare variants in Mendelian genes of cardiomyopa-
thy in the general population [106,107]. To evaluate a possible association between the Mendelian
genes studied and the APOE status, we performed the previous analysis stratified by APOE status.
We performed a second burden analysis among our unrelated cases (672 cases) or the
ADSP cases (5679) and the non-Finnish European (NFE) ExAC reference population (33,000
controls) [108]. Similarly, for the gene-based analysis in the unrelated dataset, we performed a
burden test for high or moderate variants with (i) a MAF1% and (ii) variants with AC1.
Because we do not have individual genotype data for the ExAC dataset we could not use rvtest
to perform the burden analysis. We instead performed the CMC Fisher corrected using the R
package [109] and included in the analysis those variants predicted to have a high (frameshift,
splice acceptor/donor, stop gained/lost), or moderate (in-frame deletion/insertion, missense
variant) effect according to SnpEff [100]. The frequency of variant PSEN1 rs63749824, p.
(Ala79Val) in the NFE ExAC dataset is also one allele count in 33,000 sequenced individuals.
Despite the fact that ExAC cannot be regarded as a pure control dataset, there are several stud-
ies that have used this resource as a proxy for studying variation in the human population,
with the hypothesis that variants absent in ExAC are more likely to be pathogenic [106,107].
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